

Premium NS Craft Cannabis Producer with Growing National Footprint

May 9, 2025

Opportunity overview

Grant Thornton Limited, in its capacity as Court-appointed Monitor (“**Monitor**”) of Mernova Medicinal Inc. and Creso Canada Limited (“**Mernova**” or the “**Company**”) is soliciting offers for the sale of, or investment in, the Company’s cannabis cultivation operations pursuant to the April 25, 2025 order (“**SISP Order**”) of the Supreme Court of Nova Scotia (“**Court**”). The Sales and Investment Solicitation Process (“**SISP**”) outlines the procedures by which the Monitor will seek offers in respect of the Company on an “as is, where is” basis, free and clear of any claims, debts or encumbrances.

Interested parties are encouraged to contact the Monitor for additional information and to arrange a site visit. Detailed bidding procedures, the SISP Order and a confidentiality agreement to participate in the SISP are available upon request and on the Monitor’s website: DoaneGrantThornton.ca/Mernova

Key features

The Opportunity

Mernova is a craft cannabis producer that cultivates a variety of premium products at its indoor growing and processing facility in Windsor, NS. The ~24,000 sq/ft facility on 10 acres of land has current annual capacity of 1,250 kg across six growing rooms, all of which are fully utilized with additional rooms available for expansion. Mernova is a growing private company with an efficient cost profile, increasing product yields and market penetration across 11 of Canada’s provinces and territories. With a dedicated compliment of trained staff, experienced management, profitable SKU’s across a wide range of Ritual branded cannabis products and loyal customers, Mernova presents a turn-key opportunity to invest in a rising cannabis player with Atlantic Canadian roots.

Highlights

Assets	Description
Facility	24,000 sq/ft GPP compliant facility on ~10 acres of land in Windsor, NS, with current capacity of 1,250 kgs annually
Licenses	License from Health Canada to cultivate, produce, process and sell recreational and medical cannabis products; non-therapeutic research license from Health Canada; Excise License from CRA to sell cannabis
Team	Lean staffing profile, experienced leadership, a distinguished grower and dedicated quality assurance
Brand	Ritual Green craft cannabis flower and pre-rolled products, distillate vapes, hash, edibles, live rosin vapes and dabbers and recently launched value branded 902 Rotations
Growth	Consistent revenue growth profile, with deep penetration in NS, national expansion and international opportunity



Sales process milestones

Sales process timeline

- **Launch Date:** May 9, 2025
- **Bid Deadline:** June 23, 2025
- **Selection of Successful Bid(s):** July 3, 2025
- **Sale Approval Hearing:** July 14, 2025
- **Target Closing:** Within 2 weeks of Court approval.

Next steps

Additional information including proforma financial projections and detailed asset information is available from the Monitor. Please contact Corey Hines at Corey.Hines@Doane.gt.ca for access to the Virtual Data Room (“**VDR**”) or to arrange a site visit. **All enquiries must be directed to the Monitor- Grant Thornton Limited.**



DoaneGrantThornton.ca

Bidding procedures

Key features of the process include:

- Any transaction derived from the SISP will be on an “as is, where is” basis and require Court approval, sold free and clear of claims & encumbrances.
- Template bidding documents outlining the form of transaction, which is expected to be via reverse vesting order (“**RVO**”), are available on the VDR.
- Qualified Bids require a **deposit of 10%** of the Bid Price, delivered to the Monitor at/prior to Bid Deadline.
- Further SISP details are available: DoaneGrantThornton.ca/Mernova

Corey Hines
CPA, CIRP, LIT
Manager
T +1 902 491 7704
E Corey.Hines@Doane.gt.ca

Liam Murphy
CPA, CA, CIRP, LIT
Senior Vice President
T +1 902 429 5435
E Liam.Murphy@Doane.gt.ca

Notice

This document has been prepared from the Company’s available books and records and from information obtained from external sources, none of which have been independently verified. This document and the contents of it do not, and are not intended to, constitute an offer for sale or an invitation to treat offers to purchase any company, its shares, other securities or assets. For the avoidance of doubt there is no intention to create a legal relationship, and such relationship will not come into existence unless and until a formal written contract has been entered into. The information herein has been provided to Grant Thornton Limited by the Company and the contents are not to be relied upon by potential purchasers as an inducement to enter a formal purchase contract. All enquirers or prospective purchasers must carry out their own due diligence in respect of the matters referred to and satisfy themselves as to the accuracy of all matters. While every care is taken in the preparation of this document and the information contained in it, we hereby give you notice that we cannot and do not accept any responsibility and / or liability for any loss or damage of whatsoever nature that may occur by reliance on it and howsoever arising. Any disputes or claim arising under or in connection with this document shall be subject to the non-exclusive jurisdictions of the Courts of the province of Newfoundland and Labrador, Canada. Grant Thornton Limited is acting in its capacity as the Monitor of Mernova Medicinal Inc. and Creso Canada Limited and in no other capacity.